Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study

Autor: Arnedo, Vanessa, Clark, Adrienne, Fraiser, Mark, Kopil, Catherine, Chowdhury, Sohini, Sherer, Todd, Daegele, Nichole, Casaceli, Cynthia, Dorsey, Ray, Wilson, Renee, Mahes, Sugi, Salerno, Christina, Crawford, Karen, Casalin, Paola, Malferrari, Giulia, Weisz, Mali Gani, Orr-Urtreger, Avi, Montine, Thomas, Baglieri, Chris, Christini, Amanda, Russell, David, Dahodwala, Nabila, Giladi, Nir, Factor, Stewart, Hogarth, Penelope, Standaert, David, Hauser, Robert, Jankovic, Joseph, Saint-Hilaire, Marie, Richard, Irene, Shprecher, David, Fernandez, Hubert, Brockmann, Katrina, Rosenthal, Liana, Barone, Paolo, Espay, Alberto, Rowe, Dominic, Marder, Karen, Santiago, Anthony, Hu, Shu-Ching, Isaacson, Stuart, Corvol, Jean-Christophe, Ruiz Martinez, Javiar, Tolosa, Eduardo, Tai, Yen, Politis, Marios, Smejdir, Debra, Rees, Linda, Williams, Karen, Kausar, Farah, Richardson, Whitney, Willeke, Diana, Peacock, Shawnees, Sommerfeld, Barbara, Freed, Alison, Wakeman, Katrina, Blair, Courtney, Guthrie, Stephanie, Harrell, Leigh, Hunter, Christine, Thomas, Cathi-Ann, James, Raymond, Zimmerman, Grace, Brown, Victoria, Mule, Jennifer, Hilt, Ella, Ribb, Kori, Ainscough, Susan, Wethington, Misty, Ranola, Madelaine, Mejia Santana, Helen, Moreno, Juliana, Raymond, Deborah, Speketer, Krista, Carvajal, Lisbeth, Carvalo, Stephanie, Croitoru, Ioana, Garrido, Alicia, Payne, Laura Marie, Viswanth, Veena, Severt, Lawrence, Facheris, Maurizio, Soares, Holly, Mintun, Mark A., Cedarbaum, Jesse, Taylor, Peggy, Biglan, Kevin, Vandenbroucke, Emily, Haider Sheikh, Zulfiqar, Bingol, Baris, Fischer, Tanya, Sardi, Pablo, Forrat, Remi, Reith, Alastair, Egebjerg, Jan, Ahlberg Hillert, Gabrielle, Saba, Barbara, Min, Chris, Umek, Robert, Mather, Joe, De Santi, Susan, Post, Anke, Boess, Frank, Taylor, Kirsten, Grachev, Igor, Avbersek, Andreja, Muglia, Pierandrea, Merchant, Kaplana, Tauscher, Johannes, Simuni, Tanya ^*, Uribe, Liz, Cho, Hyunkeun Ryan, Caspell-Garcia, Chelsea, Coffey, Christopher S, Siderowf, Andrew, Trojanowski, John Q, Shaw, Leslie M, Seibyl, John, Singleton, Andrew, Toga, Arthur W, Galasko, Doug, Foroud, Tatiana, Tosun, Duygu, Poston, Kathleen, Weintraub, Daniel, Mollenhauer, Brit, Tanner, Caroline M, Kieburtz, Karl, Chahine, Lana M, Reimer, Alyssa, Hutten, Samantha J, Bressman, Susan, Marek, Kenneth

Publikováno v: In The Lancet Neurology January 2020 19(1):71-80

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Development of a quantitative semi‐mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q‐ATN model).

Autor: Mazer, Norman A., Hofmann, Carsten, Lott, Dominik, Gieschke, Ronald, Klein, Gregory, Boess, Frank, Grimm, Hans Peter, Kerchner, Geoffrey A., Baudler‐Klein, Monika, Smith, Janice, Doody, Rachelle S.

Publikováno v: Alzheimer's & Dementia: The Journal of the Alzheimer's Association; Jun2023, Vol. 19 Issue 6, p2287-2297, 11p

Treatment Patterns in Patients with Incident Parkinson's Disease in the United States.

Autor: Houghton, Richard¹ (AUTHOR) richard.houghton@roche.com, Boess, Frank² (AUTHOR), Verselis, Lynne³ (AUTHOR), Ding, Yingjie⁴ (AUTHOR), Freitas, Rita¹ (AUTHOR), Constantinovici, Niculae¹ (AUTHOR), Ong, Rose¹ (AUTHOR)

Publikováno v: Journal of Parkinson's Disease. 2019, Vol. 9 Issue 4, p749-759. 11p.

Trial of Prasinezumab in Early-Stage Parkinson's Disease

Autor: Pagano, Gennaro, Taylor, Kirsten I, Mollenhauer, Brit, López-Manzanares, Lydia, Russell, David S, Boyd, James T, Nicholas, Anthony P, Luquin, María R, Hauser, Robert A, Gasser, Thomas, Poewe, Werner, Ricci, Benedicte, Anzures-Cabrera, Judith, Boulay, Anne, Vogt, Annamarie, Boess, Frank G, Dukart, Juergen, D'Urso, Giulia, Finch, Rebecca, Zanigni, Stefano, Monnet, Annabelle, Pross, Nathalie, Hahn, Andrea, Marchesi, Maddalena, Svoboda, Hanno, Britschgi, Markus, Lipsmeier, Florian, Volkova-Volkmar, Ekaterina, Lindemann, Michael, Dziadek, Sebastian, Holiga, Štefan, Rukina, Daria, Kustermann, Thomas, Kerchner, Geoffrey A, Simuni, Tanya, Fontoura, Paulo, Umbricht, Daniel, Doody, Rachelle, Nikolcheva, Tania, Bonni, Azad, Investigators, PASADENA, Group, Prasinezumab Study, Marek, Kenneth, Postuma, Ronald B, Pavese, Nicola, Stocchi, Fabrizio, Azulay, Jean-Philippe

Publikováno v: The New England journal of medicine 387(5), 421-432 (2022). doi:10.1056/NEJMoa2202867

Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson's disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson's disease.In this phase 2 trial, we ra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eed8113a77bcb1ffa9116a659e579d4d
https://pub.dzne.de/record/165174